Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells.

por Barham, H. M., Inglis, R., Chinje, E. C., Stratford, I. J.
Publicado 1996

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line

por Saunders, M P, Patterson, A V, Chinje, E C, Harris, A L, Stratford, I J
Publicado 2000

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

por Chinje, E C, Patterson, A V, Saunders, M P, Lockyer, S D, Harris, A L, Stratford, I J
Publicado 1999

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

por Patterson, A. V., Barham, H. M., Chinje, E. C., Adams, G. E., Harris, A. L., Stratford, I. J.
Publicado 1995

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

por Patterson, A. V., Saunders, M. P., Chinje, E. C., Talbot, D. C., Harris, A. L., Strafford, I. J.
Publicado 1997

17β-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response

por Chinje, E C, Williams, K J, Telfer, B A, Wood, P J, van der Kogel, A J, Stratford, I J
Publicado 2002